Autologous ex vivo expanded cd4+-enriched leukocytes treated with the de-methylating agent 5-aza-deoxycytidine
DB19219InvestigationalCell transplant therapies
Autologous ex vivo expanded cd4+-enriched leukocytes treated with the de-methylating agent 5-aza-deoxycytidine: Overview.
- Also known as
- ALECSAT · ALECSAT-GBM
Resolves to
Compound
What you can answer from here — as of July 10, 2024
Which companies are running trials of Autologous ex vivo expanded cd4+-enriched leukocytes treated with the de-methylating agent 5-aza-deoxycytidine, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account